Predicting Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
Launched by ASSIUT UNIVERSITY · Jul 6, 2024
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how well a specific marker called CD10 can help predict how patients with locally advanced breast cancer will respond to neoadjuvant chemotherapy, which is treatment given before surgery. While chemotherapy can improve outcomes for many patients, not everyone responds the same way. The trial aims to find out if measuring CD10 levels in tumor samples can help doctors better understand which patients are likely to benefit from this treatment.
To participate in the trial, you must be an adult over 18 years old with a confirmed diagnosis of locally advanced breast cancer. Unfortunately, patients with metastatic disease (cancer that has spread to other parts of the body), those with other primary cancers, or those who cannot receive chemotherapy are not eligible. If you join the study, you can expect to have your tumor tests analyzed to see if CD10 can help guide treatment decisions. This research could ultimately lead to more personalized and effective treatment plans for breast cancer patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients above 18 years
- • Pathologically proven breast carcinoma
- • Locally advanced breast cancer
- Exclusion Criteria:
- • Patients below 18 years.
- • Patients with metastatic disease
- • Patients with second primary cancer
- • Patients ineligible for chemotherapy
About Assiut University
Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported